Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

related to degree

  • Lee, Jeong Hyun, Ph.D. in Chemical Biology, Scripps Research 2011 - 2016
  • Murin, Charles Daniel, Ph.D. in Biophysics, Scripps Research 2011 - 2016

authors

  • Kong, L.
  • Lee, Jeong Hyun
  • Doores, K. J.
  • Murin, Charles Daniel
  • Julien, J. P.
  • McBride, R.
  • Liu, Y.
  • Marozsan, A.
  • Cupo, A.
  • Klasse, P. J.
  • Hoffenberg, S.
  • Caulfield, M.
  • King, C. R.
  • Hua, Y.
  • Le, K. M.
  • Khayat, R.
  • Deller, M. C.
  • Clayton, T.
  • Tien, H.
  • Feizi, T.
  • Sanders, R. W.
  • Paulson, James
  • Moore, J. P.
  • Stanfield, Robyn
  • Burton, Dennis
  • Ward, Andrew
  • Wilson, Ian

publication date

  • July 2013

journal

  • Nature Structural & Molecular Biology  Journal

abstract

  • A substantial proportion of the broadly neutralizing antibodies (bnAbs) identified in certain HIV-infected donors recognize glycan-dependent epitopes on HIV-1 gp120. Here we elucidate how the bnAb PGT 135 binds its Asn332 glycan-dependent epitope from its 3.1-? crystal structure with gp120, CD4 and Fab 17b. PGT 135 interacts with glycans at Asn332, Asn392 and Asn386, using long CDR loops H1 and H3 to penetrate the glycan shield and access the gp120 protein surface. EM reveals that PGT 135 can accommodate the conformational and chemical diversity of gp120 glycans by altering its angle of engagement. Combined structural studies of PGT 135, PGT 128 and 2G12 show that this Asn332-dependent antigenic region is highly accessible and much more extensive than initially appreciated, which allows for multiple binding modes and varied angles of approach; thereby it represents a supersite of vulnerability for antibody neutralization.
  • A substantial proportion of the broadly neutralizing antibodies (bnAbs) identified in certain HIV-infected donors recognize glycan-dependent epitopes on HIV-1 gp120. Here we elucidate how the bnAb PGT 135 binds its Asn332 glycan-dependent epitope from its 3.1-Å crystal structure with gp120, CD4 and Fab 17b. PGT 135 interacts with glycans at Asn332, Asn392 and Asn386, using long CDR loops H1 and H3 to penetrate the glycan shield and access the gp120 protein surface. EM reveals that PGT 135 can accommodate the conformational and chemical diversity of gp120 glycans by altering its angle of engagement. Combined structural studies of PGT 135, PGT 128 and 2G12 show that this Asn332-dependent antigenic region is highly accessible and much more extensive than initially appreciated, which allows for multiple binding modes and varied angles of approach; thereby it represents a supersite of vulnerability for antibody neutralization.

subject areas

  • 1-Deoxynojirimycin
  • Alkaloids
  • Amino Acid Motifs
  • Amino Acid Sequence
  • Antibodies, Neutralizing
  • Antigen-Antibody Reactions
  • Antigens, CD4
  • Binding Sites, Antibody
  • Biopolymers
  • Carbohydrate Sequence
  • Crystallography, X-Ray
  • Epitopes
  • Glycosylation
  • HEK293 Cells
  • HIV Antibodies
  • HIV Envelope Protein gp120
  • Humans
  • Immunoglobulin Fab Fragments
  • Microscopy, Electron
  • Models, Molecular
  • Molecular Docking Simulation
  • Molecular Sequence Data
  • Polysaccharides
  • Protein Conformation
  • Protein Processing, Post-Translational
  • Structure-Activity Relationship
  • env Gene Products, Human Immunodeficiency Virus
scroll to property group menus

Identity

PubMed Central ID

  • PMC3823233

International Standard Serial Number (ISSN)

  • 1545-9993

Digital Object Identifier (DOI)

  • 10.1038/nsmb.2594

PubMed ID

  • 23708606
scroll to property group menus

Additional Document Info

start page

  • 796

end page

  • 803

volume

  • 20

issue

  • 7

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support